| 2.835 0.15 (5.59%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.93 | 1-year : | 4.67 |
| Resists | First : | 3.36 | Second : | 4 |
| Pivot price | 2.94  |
|||
| Supports | First : | 2.35 | Second : | 1.95 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 3.06 |
| MA(100) : | 2.09 |
MA(250) : | 2.18 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 21.3 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 4 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRVI ] has closed above bottom band by 37.8%. Bollinger Bands are 28.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.92 - 2.94 | 2.94 - 2.95 |
| Low: | 2.56 - 2.57 | 2.57 - 2.59 |
| Close: | 2.81 - 2.83 | 2.83 - 2.86 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Thu, 18 Apr 2024
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Tue, 09 Apr 2024
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference ... - Financial Times
Thu, 04 Apr 2024
Trevi Therapeutics to Participate in Upcoming April Events - PR Newswire
Tue, 02 Apr 2024
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team - PR Newswire
Thu, 21 Mar 2024
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript March 20, 2024 - Yahoo Finance
Wed, 20 Mar 2024
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 80.7 (%) |
| Shares Short | 1,040 (K) |
| Shares Short P.Month | 1,240 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20 % |
| Return on Equity (ttm) | -30.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -9.78 |
| PEG Ratio | 0 |
| Price to Book value | 2.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|